| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/00054725-200403000-00002 |
| P8608 | Fatcat ID | release_mcyp7ch6lndrjarudfnxzwqjfe |
| P698 | PubMed publication ID | 15168804 |
| P5875 | ResearchGate publication ID | 8537507 |
| P50 | author | Joris Casselman | Q2690719 |
| Séverine Vermeire | Q30247983 | ||
| Paul Rutgeerts | Q30247987 | ||
| Gert Van Assche | Q37064266 | ||
| Geert D'Haens | Q37066728 | ||
| André D'Hoore | Q91759942 | ||
| Martin Hiele | Q114416452 | ||
| Freddy Penninckx | Q114416453 | ||
| P2093 | author name string | Miranda Zeegers | |
| P2860 | cites work | Factors predictive of response to cyclosporin treatment for severe, steroid-resistant ulcerative colitis | Q34009451 |
| Cyclosporine in severe ulcerative colitis refractory to steroid therapy | Q34060783 | ||
| Predicting outcome in severe ulcerative colitis | Q34409849 | ||
| THE COURSE AND PROGNOSIS OF ULCERATIVE COLITIS. | Q34478028 | ||
| A comparison of the quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous cyclosporin | Q41608680 | ||
| Cyclosporine therapy in inflammatory bowel disease: short-term and long-term results | Q41689243 | ||
| Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis | Q43582796 | ||
| Short- and long-term outcome of patients treated with cyclosporin for severe acute ulcerative colitis. | Q54118693 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 73-78 | |
| P577 | publication date | 2004-03-01 | |
| P1433 | published in | Inflammatory Bowel Diseases | Q15749161 |
| P1476 | title | Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis | |
| P478 | volume | 10 |
| Q46846798 | A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization |
| Q37226310 | Aberrant activation of nuclear factor of activated T cell 2 in lamina propria mononuclear cells in ulcerative colitis |
| Q38942561 | Acute severe ulcerative colitis: from pathophysiology to clinical management |
| Q49232336 | Acute severe ulcerative colitis: latest evidence and therapeutic implications |
| Q37051414 | Adverse events associated with the use of cyclosporine in patients with inflammatory bowel disease |
| Q38179381 | Biologic therapy and surgery for crohn disease |
| Q53122367 | Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. |
| Q35841818 | Coadministration of cyclosporin a with prednisolone in acute interstitial pneumonia complicating polymyositis/dermatomyositis |
| Q37365308 | Colectomy in patients with acute colitis: a systematic review. |
| Q55113137 | Colon-targeted delivery of cyclosporine A using dual-functional Eudragit® FS30D/PLGA nanoparticles ameliorates murine experimental colitis. |
| Q38293796 | Conventional drug therapy for inflammatory bowel disease |
| Q64055217 | Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review |
| Q46894465 | Current status of treatment of inflammatory bowel disease |
| Q38056526 | Cyclosporine in patients with severe steroid refractory ulcerative colitis in the era of infliximab. Review article |
| Q38365426 | Early investigational TNF receptor antagonists for the treatment of ulcerative colitis |
| Q37727232 | Efficacy and safety of drugs for ulcerative colitis |
| Q36637710 | Efficacy of infliximab in acute severe ulcerative colitis: a single-centre experience |
| Q36478109 | Emerging biological treatments in inflammatory bowel diseases |
| Q34025054 | European evidence-based Consensus on the management of ulcerative colitis: Current management |
| Q90135118 | Evaluation of Invasive Intra-abdominal Candidiasis in Crohn Disease at the Time of Surgery |
| Q34647681 | Granulo-monocyto apheresis is more effective in mild ulcerative colitis than in moderate to severe disease. |
| Q33654733 | Hepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease |
| Q37701805 | Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease |
| Q38060831 | Immunosuppressive and biologic therapy for ulcerative colitis. |
| Q36419073 | Immunosuppressive drugs in ulcerative colitis: twisting facts to suit theories? |
| Q50988136 | Incidence of and impact of medications on colectomy in newly diagnosed ulcerative colitis in the era of biologics. |
| Q37050242 | Infections and IBD. |
| Q36745440 | Inflammatory bowel disease: past, present, and future |
| Q30502980 | Inflammatory bowel disease: perioperative pharmacological considerations |
| Q36580286 | Infliximab in ulcerative colitis |
| Q37957998 | Infliximab or cyclosporine for acute severe ulcerative colitis: a retrospective analysis. |
| Q36037115 | Infliximab versus Cyclosporine Treatment for Severe Corticosteroid-Refractory Ulcerative Colitis: A Korean, Retrospective, Single Center Study. |
| Q37196938 | Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial |
| Q45947185 | Infliximab versus ciclosporin in severe ulcerative colitis. |
| Q34449876 | Infliximab: the evidence for its place in therapy in ulcerative colitis. |
| Q46915113 | Is oral ciclosporin necessary to switch from i.v. to thiopurines? |
| Q38694769 | Long-Term Efficacy and Safety of Cyclosporine in a Cohort of Steroid-Refractory Acute Severe Ulcerative Colitis Patients from the ENEIDA Registry (1989-2013): A Nationwide Multicenter Study. |
| Q89303880 | Long-Term Outcomes of Immunosuppression-Naïve Steroid Responders Following Hospitalization for Ulcerative Colitis |
| Q43496310 | Long-term effects and colectomy rates in ulcerative colitis patients treated with infliximab: a Danish single center experience |
| Q40396288 | Low Risk of Pneumonia From Pneumocystis jirovecii Infection in Patients With Inflammatory Bowel Disease Receiving Immune Suppression |
| Q46642635 | Low-dose oral microemulsion ciclosporin for severe, refractory ulcerative colitis |
| Q43446380 | Management of severe or corticosteroid resistant ulcerative colitis |
| Q42116204 | Managing acute severe ulcerative colitis in the hosptialised setting |
| Q26777729 | Medical Therapy of Active Ulcerative Colitis |
| Q35939984 | Medical therapy for ulcerative colitis: the state of the art and beyond |
| Q40415198 | Medical treatment and management of severe ulcerative colitis |
| Q36171733 | Methods to avoid infections in patients with inflammatory bowel disease |
| Q33268368 | Multidrug resistance gene-1 polymorphisms and resistance to cyclosporine A in patients with steroid resistant ulcerative colitis. |
| Q33372802 | Native valve Aspergillus endocarditis in two patients with aplastic anaemia |
| Q34569872 | Novel biological therapies for inflammatory bowel disease |
| Q37876204 | Novel topical therapies for distal colitis |
| Q30664895 | Outcomes of rescue therapy in acute severe ulcerative colitis: data from the United Kingdom inflammatory bowel disease audit |
| Q26768280 | Pharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adults |
| Q47780165 | Pneumocystis carinii pneumonia infection in a patient with known chronic mucocutaneous candidiasis |
| Q40100993 | Pneumocystis jirovecii Pneumonia in Pediatric Inflammatory Bowel Disease: A Case Report and Literature Review |
| Q64101217 | Preclinical evaluation of EPHX2 inhibition as a novel treatment for inflammatory bowel disease |
| Q36948496 | Prophylaxis against Pneumocystis pneumonia in patients with inflammatory bowel disease: toward a standard of care |
| Q35100726 | Pros and cons of medical management of ulcerative colitis |
| Q38049067 | Readministration of calcineurin inhibitors for ulcerative colitis |
| Q38815035 | Recent trends and future directions for the medical treatment of ulcerative colitis. |
| Q50942285 | Rescue therapy: ciclosporin or infliximab? |
| Q38501680 | Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment |
| Q36305931 | Review article: how and when to use ciclosporin in ulcerative colitis |
| Q36589437 | Review article: saving the colon in severe colitis - the case for medical therapy |
| Q35883580 | Review article: the practical management of acute severe ulcerative colitis |
| Q37817487 | Review article: the role of non-biological drugs in refractory inflammatory bowel disease |
| Q39251794 | Reviewing treatments and outcomes in the evolving landscape of ulcerative colitis |
| Q92178119 | Risk Factors for Mortality in Pneumocystis jirovecii Pneumonia in Patients with Inflammatory Bowel Disease |
| Q80113057 | Role of cyclosporin in preventing or delaying colectomy in children with severe ulcerative colitis |
| Q37189011 | Steroid-refractory severe ulcerative colitis: what are the available treatment options? |
| Q46873505 | Steroid-refractory ulcerative colitis: predictive factors of response to cyclosporine and validation in an independent cohort |
| Q34484121 | Strategies for the care of adults hospitalized for active ulcerative colitis |
| Q38575522 | Surgical and medical treatment in patients with acute severe ulcerative colitis |
| Q38726448 | Systematic Review and Meta-Analysis: Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to Steroids |
| Q31004717 | Tacrolimus or infliximab for severe ulcerative colitis: short-term and long-term data from a retrospective observational study |
| Q35768958 | Tacrolimus--finally! |
| Q37141131 | The use of infliximab for treatment of hospitalized patients with acute severe ulcerative colitis |
| Q37816246 | The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease |
| Q37345935 | Therapeutic options in acute severe ulcerative colitis |
| Q38180807 | Therapeutic peptides in inflammatory bowel disease |
| Q37318035 | Therapeutic strategies for the management of ulcerative colitis. |
| Q38778842 | There is Significant Practice Pattern Variability in the Management of the Hospitalized Ulcerative Colitis Patient at a Tertiary Care and IBD Referral Center. |
| Q34225376 | Toxic megacolon |
| Q37305793 | Treatment of choice for acute severe steroid-refractory ulcerative colitis is remicade |
| Q37276958 | Treatment of severe steroid refractory ulcerative colitis |
| Q38258440 | Tumor necrosis factor-alpha antagonists twenty years later: what do Cochrane reviews tell us? |
| Q84851901 | Ulcerative colitis |
| Q84278827 | Ulcerative colitis: Rescue immune suppression for severe colitis--worth the risk? |
| Q38103628 | Ulcerative colitis: prevention of relapse. |
| Q40777140 | Use of Serum Infliximab Level Prior to Cyclosporine Salvage Therapy in Severe Ulcerative Colitis |
| Q37256032 | Use of infliximab in the prevention and delay of colectomy in severe steroid dependant and refractory ulcerative colitis |
| Q38191583 | What is left when anti-tumour necrosis factor therapy in inflammatory bowel diseases fails? |
| Q37279167 | What is the prognosis of ulcerative colitis? |
Search more.